Abstract:

Background: MDR-TB (Multidrug-resistant tuberculosis) reportedly proves to be the greatest public health issue on a global scale. The mutation tendency of Mycobacterium tuberculosis substantially elevates its resistance against the recommended pharmacotherapeutic interventions. Limited information on the MDR-TB diagnostic approaches and treatment options is primarily responsible for its extensive progression across resource-limited regions. The frequently reported adverse effects of the standard therapies barricade their long-term use by the MDR-TB patients.

Aim: The presented narrative review attempts to consolidate and strengthen the clinical evidence for improving the MDR-TB diagnosis and treatment decisions in health care settings.

Methods: The author performed an evidence-based analysis of the causative factors, pathophysiology, diagnostic techniques, and treatment options/challenges for MDR-TB through the systematic exploration of databases including Google Scholar, PubMed/Medline, and Cochrane Library. The utilization of these databases was effectively undertaken to explore the peer-reviewed MDR-TB-related articles based on meta-analysis, systematic review, retrospective study, randomized controlled trial, and narrative literature reviews.

Findings: The study findings revealed MDR-TB epidemiology, etiology, diagnostic approaches, preventive measures, pathogenesis, treatment adversities, and therapeutic potential in the context of controlling the prevalence of drug-resistant tuberculosis and related comorbidities.

Conclusion: The study findings advocate the need for improving the overall MDR-TB investigation and treatment process to control the elevated prevalence of MDR-TB among the suspected patients. The study outcomes advocate the requirement of multidisciplinary coordination between clinicians and researchers to effectively improve the medical decision-making quality for enhancing the therapeutic outcomes of MDR-TB patients.

Keywords: MDR-TB, Drug-resistant, tuberculosis, diagnosis, pathophysiology, treatment.

References:

[1].     Adigun, R., & Singh, R. (2019). Tuberculosis. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK441916/.

[2].     Caminero, J. A., Sotgiu, G., Zumla, A., & Migliori, G. B. (2010). Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. The Lancet - Infectious Diseases, 10(9), 621-629. doi:10.1016/S1473-3099(10)70139-0.

[3].     Chang, K. C., & Yew, W. W. (2013). Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Respirology, 8-21. doi:10.1111/j.1440-1843.2012.02257.x.

[4].     Davies, P. D. (2001). Drug-resistant tuberculosis. JRSM, 94(6), 261-263. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1281517/.

[5].     Dean, A. S., Cox, H., & Zignol, M. (2017). Epidemiology of Drug-Resistant Tuberculosis. Advances in Experimental Medicine and Biology, 209-220. doi:10.1007/978-3-319-64371-7_11.

[6].     Dodd, P. J. (2016). Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. The Lancet - Infectious Diseases, 1193-1201. doi: https://doi.org/10.1016/S1473-3099(16)30132-3.

[7].     Gilpin, C., Korobitsyn, A., & Weyer, K. (2016). Current tools available for the diagnosis of drug-resistant tuberculosis. Therapeutic Advances in Infectious Disease, 3(6), 145-151. doi:10.1177/2049936116673553.

[8].     Girum, T., Muktar, E., Lentiro, K., Wondiye, H., & Shewangizaw, M. (2018). Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Tropical Diseases, Travel Medicine, and Vaccines, 1-12. doi:10.1186/s40794-018-0065-5.

[9].     Gordon, S. V., & Parish, T. (2018). Microbe Profile: Mycobacterium tuberculosis: Humanity's deadly microbial foe. Microbiology, 164(4), 437-439. doi:10.1099/mic.0.000601.

[10]. He, X. C., Zhang, X. X., Zhao, J. N., Liu, Y., Yu, C. B., Yanag, G. R., & Li, H. C. (2016). Epidemiological Trends of Drug-Resistant Tuberculosis in China From 2007 to 2014-A Retrospective Study. Medicine, 95(15), 1-7. doi:10.1097/MD.0000000000003336.

[11]. Heemskerk, D., Caws, M., & Marais, B. (2015). Chapter 6Prevention. In Tuberculosis in Adults and Children. London, UK: Springer. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK344409/.

[12]. IOM. (2011). The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop. In Diagnosis of Drug-Resistant TB. Washington (DC): National Academies Press. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK62450/.

[13]. Jeon, D. (2017). WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea. Tuberculosis and Respiratory Diseases, 80(4), 336-343. doi:10.4046/trd.2017.0049.

[14]. Kanabus, A. (2018). Multi Drug Resistant TB - What is MDR, statistics, treatment. (GHE) Retrieved from Information about Tuberculosis: www.tbfacts.org.

[15]. Koch, A., Cox, H., & Mizrahi, V. (2018). Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Current Opinion in Pharmacology, 7-15. doi: 10.1016/j.coph.2018.05.013.

[16]. Lange, C., Chesov, D., Heyckendorf, J., Leung, C. C., Udwadia, Z., & Dheda, K. (2018). Drug‐resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology. doi: https://doi.org/10.1111/resp.13304.

[17]. Migliori, G. B., Matteelli, A., Cirillo, D., & Pai, M. (2008). Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges. Canadian Journal of Infectious Diseases and Medical Microbiology, 19(2), 169-172. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605858/.

[18]. Pinto, L., & Menzies, D. (2011). Treatment of drug-resistant tuberculosis. Infection and Drug Resistance, 129-135. doi: 10.2147/IDR.S10332.

[19]. Podany, A. T., & Swindells, S. (2016). Current strategies to treat tuberculosis. F1000Research, 1-8. doi:10.12688/f1000research.7403.1.

[20]. Prasad, R. (2012). Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies. Lung India, 29(2), 154-159. doi:10.4103/0970-2113.95321.

[21]. Ryu, Y. J. (2015). Diagnosis of Pulmonary Tuberculosis: Recent Advances and Diagnostic Algorithms. Tuberculosis and Respiratory DIseases, 78(2), 64-71. doi:10.4046/trd.2015.78.2.64.

[22]. Samuels, J. P., Sood, A., Campbell, J. R., Khan, F. A., & Johnston, J. C. (2018). Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Scientific Reports. doi:10.1038/s41598-018-23344-z.

[23]. Schaaf, H. S. (2019). Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach. Indian Journal of Pediatrics, 86(8), 717-724. doi:10.1007/s12098-018-02846-8.

[24]. Seung, K. J., Keshavjee, S., & Rich, M. L. (2015). Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 5(9), 1-20. doi:10.1101/cshperspect.a017863.

[25]. Sharma, S. K., & Mohan, A. (2004). Multidrug-resistant tuberculosis. The Indian Journal of Medical Research, 354-376. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15520486.

[26]. Sharma, S. K., Sharma, A., Kadhiravan, T., & Tharyan, P. (2013). Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative people at risk of active TB. Cochrane Database of Systematic Reviews. doi: https://doi.org/10.1002/14651858.CD007545.pub2.

[27]. Sotgiu, G., Centis, R., D’ambrosio, L., & Migliori, G. B. (2015). Tuberculosis Treatment and Drug Regimens. Gold Spring Harbor Perspectives in Medicine, 5(5), 1-12. doi:10.1101/cshperspect.a017822.

[28]. Venkatesh, U., Srivastava, D. K., Srivastava, A. K., & Tiwari, H. C. (2018). Epidemiological profile of multidrug-resistant tuberculosis patients in Gorakhpur Division, Uttar Pradesh, India. Journal of Family Medicine and Primary Care, 7(3), 589-595. doi:10.4103/jfmpc.jfmpc_99_17.

[29]. WHO. (2019). Tuberculosis (TB). Retrieved from https://www.who.int/tb/areas-of-work/drug-resistant-tb/totally-drug-resistant-tb-faq/en/.

[30]. Yang, T. W., Park, H. O., Jang, H. N., Yang, J. H., Kim, S. H., Moon, S. H., . . . Kang, D. H. (2017). Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea-A retrospective study. Medicine, 96(28), 1-5. doi:10.1097/MD.0000000000007482.